Novartis' Tafinlar/Mekinist combo scores new indication in pediatric brain cancer

Novartis’ Tafinlar (dabrafenib) and Mekinist (trametinib) combo has been approved for another indication by the FDA — this time for treatment of low-grade glioma with a BRAF V600E mutation in kids aged 1 year and up.